GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2007

Cornell Scientist Awarded $10M to Enhance Cellulose-to-Biofuel Research

  • Cornell professor of biological and environmental engineering Larry Walker received a $10 million grant from Empire State Development to advance technologies that convert perennial grasses and woody biomass to ethanol. The grant will be used to upgrade the university’s industrial biotechnology laboratories.

    "Although corn-based ethanol production is the current state-of-the-art technology, the future development, success, and sustainability of the U.S. ethanol industry hinges on developing and converting perennial grasses and woody biomass, cellulosic biomass, to ethanol," Walker points out.

    The money will be used to renovate laboratories in Riley Robb Hall and to purchase fermenters, incubators, and analytical equipment. It also will improve researchers' abilities to overcome the physical, chemical, and biological barriers to liberating sugars from such energy crops as switchgrass, miscanthus, and other perennial grasses as well as woody biomass and to biologically convert these sugars into such biofuels as ethanol, butanol, or hydrogen.

    "Cellulosic ethanol production could be economically advantageous for New York state because we know how to grow grasses and woody biomass, and we know how to implement biotechnology,” says Walker, who additionally is editor in chief of Industrial Biotechnology, published by Mary Ann Liebert that also publishes GEN. “These activities are core to the industrial biotechnology component to the evolving New York biofuels sector.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »